Spiegel R. — Psychopharmacology: an introduction :: Электронная библиотека попечительского совета мехмата МГУ

Главная Ex Libris Книги Журналы Статьи Серии Каталог Wanted Загрузка ХудЛит Справка Поиск по индексам Поиск Форум

Авторизация

Поиск по указателям

Spiegel R. — Psychopharmacology: an introduction

Обсудите книгу на научном форуме

Нашли опечатку?
Выделите ее мышкой и нажмите Ctrl+Enter

Название: Psychopharmacology: an introduction

Автор: Spiegel R.

Аннотация:

Describes the latest advances in psychopharmacology - one of the most rapidly developing fields in modern science. This latest edition has been updated to cover new developments in drug therapy and research including newly introduced antipsychotics, antidepressants and antidementia drugs. Sections on the treatment of depression and dementia have been revised to include new developments in treatment strategies. It will be welcomed for its essentially clinical and psychological approach to modern pharmaceuticals, their therapeutic uses and limitations, adverse reactions and future directions for research.

Язык:

Рубрика: Медицина и здравоохранение/

Статус предметного указателя: Готов указатель с номерами страниц

ed2k: ed2k stats

Издание: fouth edition

Год издания: 2003

Количество страниц: 400

Добавлена в каталог: 11.12.2005

Операции: Положить на полку | Скопировать ссылку для форума | Скопировать ID

Предметный указатель

Pharmacology, behavioral      129
Pharmacology, human      57 183—186
Pharmacopsychology      58
Pharmacopsychology, sensitivity of assessment methods      91—95
Pharmacopsychology, sensitivity of assessment methods, dose-effect studies      91
Pharmacotherapy      9 26
Pharmacotherapy and psychotherapy      271
Pharmacy and Therapeutics Committees (P&T Committees)      303
Phenanthrene alkaloid      256
Phencyclidine      117 131
Phenelzine      126 294
Phenobarbital      161
Phenobarbitone      284
Phenothiazine      49
Phobias, specific      291
Phosphatidylinositol, cleavage products of      104
Phosphorus, $(^{31}P)$ in MRI      211 226
Phy totherapeutics      100
Physical conditions      18
Physostigmine      89
Pilocarpine      89 221
Pimozide      5 163
Pimozide, effects of      77 79 89
Pinel, P.      34
Piperidine      256
Piracetam      26 87 89
Placebo      11—13 60 83 87 92 262 275 277 280
Placebo, active      284
Placebo, controlled trials      56 61 76—77 152—153 248—249 267 280—282
Placebo, controlled trials, design of      169—173 (171)
Placebo, effects, factor responsible for      168
Placebo, hazards of      151
Placebo, responses, reduction of      170
Placebo, studies, alternatives to      173—174
Placebo, studies, comparative      263 271 287 289 292—293 315
Placebo, studies, design of      166—173
Placebo, studies, historical data from      174
Plasma concentration curve      158
Plater, F.      31
Pneumonia      254
POC      see proof of concept studies
Poisons, inhalation      59
Poisons, inhalation, paralysing action of      60
Polyuria      17
POMS      see Profile of Mood States
Poppy, opium      28
Poppy, opium, cultivation by Sumerians      28
Poppy, opium, historical uses of      28 30
Poppy, opium, Stone Age remains of      28
Poppy, opium, symbolism of      28
Positive and Negative Syndrome Scale (PANSS)      154 202 232—233
Positron emission tomography (PET)      70 109 162—164 210—211 219—220 225 324 Plate
Positron emission tomography (PET), fluorine $(^{18}F)$ use in (FDG-PET)      215—218 (216) 226
Post-traumatic stress disorder (PTSD)      23 167 169 188 242 291—292
Post-traumatic stress disorder (PTSD), scales for      201
Postsynaptic membrane      105
Prazepam      19
Prazine $\textregistered$       5
Preclinical research in psychopharmacology      99—144
Preclinical research in psychopharmacology, the target      100—110
Preclinical research in psychopharmacology, the target, interaction between ligand and receptor      109
Preclinical research in psychopharmacology, the target, ligands      108—109
Preclinical research in psychopharmacology, the target, neurons      101—102
Preclinical research in psychopharmacology, the target, neurotransmitters      110
Preclinical research in psychopharmacology, the target, receptors      106—107
Preclinical research in psychopharmacology, the target, synapses      102—106
Preclinical research in psychopharmacology, the target, the nervous system      100—101
Precursor      105
Precursor, administration of      125
Predictor studies      194
Pregnancy and lactation      194
Prepulse inhibition (PPI) paradigm      131
Present State Examination (PSE)      199
Presynaptic membrane      105
Preventive therapy      278
Priapism      14
Procaine      38
Profile of Mood States (POMS)      64
Prolactin      7
Prolixin $\textregistered$       5
Promazine      5
Promethazine      38 41 114
Proof of concept (POC) studies/trials      97 147 186—190
Proof of concept (POC) studies/trials, challenge paradigms in      187—189
Proof of concept (POC) studies/trials, requirements of      189
Proof-of-efficacy      187
Proof-of-mechanism      187
Propanolol      296
Prosom $\textregistered$       19
Protactyl $\textregistered$       5
Proteomic approach      140
Protriptyline      12 13
Provigil $\textregistered$       25
Prozac $\textregistered$       11
Prussic acid      34
PSE      see Present State Examination
Psoriasis      17
Psychiatric indications, animal models for      128—143
Psychiatric therapy      37
Psychiatry      38 40—12
Psychiatry, advances in      46
Psychiatry, affected by psychopharmacology      319—321
Psychiatry, biological      319
Psychiatry, biological, basis of      49
Psychiatry, development of      32
Psychiatry, nineteenth century advances in      34
Psychiatry, research in      320
Psychic energizers      23
Psychoanaleptics      23
Psychoanalysis      49
Psychological instruments      93—94
Psychologists as prescribes      321—323
Psychologists, opportunities for      321
Psychology and psychotropic drugs      323—324
Psychology, impact of psychopharmacology on      321—324
Psychology, new knowledge for      59
Psychology, occupational      70 324
Psychology, traffic      70 324
Psychomotor impairment      293
Psychomotor performance      162
Psychopharmaceuticals      2 50
Psychopharmaceuticals and history of psychiatry      29—32
Psychopharmaceuticals, knowledge about, increasing importance of      323
Psychopharmaceuticals, mode of operation      99—100
Psychopharmaceuticals, sources      100
Psychopharmacology      50
Psychopharmacology and health economics      301—317
Psychopharmacology and health economics, perspectives of economic analysis      304—305
Psychopharmacology, basics of clinical practice      153—164
Psychopharmacology, basics of clinical practice, diagnosis and patient selection      153—155
Psychopharmacology, basics of clinical practice, endpoints and markers      162—164
Psychopharmacology, basics of clinical practice, pharmacokinetic-pharmacodynamic aspects      155—162
Psychopharmacology, before chlorpromazine      32—36
Psychopharmacology, clinical research in      145—205
Psychopharmacology, clinical research in, ethical aspects of      148—153
Psychopharmacology, drug development, phases of      183—194
Psychopharmacology, drug development, phases of, Phase I trials      183—186
Psychopharmacology, drug development, phases of, Phase IIa trials      147 186—190 190—193
Psychopharmacology, drug development, phases of, Phase III trials      147 190—193
Psychopharmacology, drug development, phases of, Phase IV trials      193—194
Psychopharmacology, drug development, phases of, proof-of-concept trials      147
Psychopharmacology, effect on psychiatry      319—321
Psychopharmacology, history of      27—56
Psychopharmacology, history of, important substances      29—29
Psychopharmacology, history of, important substances in      28—29
Psychopharmacology, history of, in the ancient world and Middle Ages      28—32
Psychopharmacology, history of, the past twenty years [1980—2000]      50—54
Psychopharmacology, impact on psychology      321—324
Psychopharmacology, neuroimaging studies in      207—226
Psychopharmacology, neurophysiological parameters in      71—72

Psychopharmacology, preclinical research in      99—144
Psychopharmacology, study designs      164—183
Psychopharmacology, study designs, alternatives to placebo      173—174
Psychopharmacology, study designs, bias minimization methodology      179—180
Psychopharmacology, study designs, case-control studies      182
Psychopharmacology, study designs, comparative      174—178
Psychopharmacology, study designs, longitudinal      180—182
Psychopharmacology, study designs, need for control of      164—165
Psychopharmacology, study designs, placebo-controlled designs      166—173
Psychopharmacology, study designs, psychopharmacology, study designs, parallel-group designs      165—166
Psychopharmacology, study designs, within patient      178—179
Psychopharmacology, symptom assessment      195—205
Psychopharmacology, symptom assessment, diagnosis-specific rating instruments      197—204
Psychopharmacology, symptom assessment, observation of behavior      195—196
Psychopharmacology, symptom assessment, questioning of patients      195
Psychopharmacology, symptom assessment, rating scales      196—197
Psychoses      6 14 169 186
Psychoses, biochemistry of      49
Psychoses, catatonic      3—4
Psychoses, emotional      40
Psychoses, manic-depressive      40
Psychoses, paranoid      3
Psychoses, scales for      201—202
Psychoses, schizophrenic      3 115
Psychoses, symptomatic      40
Psychoses, treatment resistant      51
Psychosomatic conditions      18
Psychostimulant drugs (psychostimulants)      2—3 58 95 246—257 263
Psychostimulant drugs (psychostimulants) and schizophrenia      131
Psychostimulant drugs (psychostimulants) on healthy subjects      76
Psychostimulant drugs (psychostimulants), abuses of      24
Psychostimulant drugs (psychostimulants), actions and uses of      23—25
Psychostimulant drugs (psychostimulants), best known      25
Psychostimulant drugs (psychostimulants), cognitive abnormalities in ADHD      246—247
Psychostimulant drugs (psychostimulants), effects of      92 247—252
Psychostimulant drugs (psychostimulants), experiments on      85—87
Psychostimulant drugs (psychostimulants), experiments on, behavioral effects      86—87
Psychostimulant drugs (psychostimulants), experiments on, neurophysiology      87
Psychostimulant drugs (psychostimulants), experiments on, subjective effects      85
Psychostimulant drugs (psychostimulants), problems with      261
Psychostimulant drugs (psychostimulants), treatment of ADHD by      296—298
Psychostimulant drugs (psychostimulants), treatment of ADHD by, drug therapy and psychotherapy      297—298
Psychostimulant drugs (psychostimulants), treatment of ADHD by, long-term medication      296—297
Psychosurgery      46
Psychotherapy      9 20
Psychotherapy and drug therapy      269—274 294—295 297—299
Psychotherapy and drug therapy, comparative studies      269—270
Psychotherapy and drug therapy, studies of      270—274
Psychotherapy and drug therapy, studies of, long-term      270
Psychotherapy, group      274
Psychotherapy, individual      273
Psychotic syndromes      3
Psychotonics      23
Psychotrophic drugs      61—62 64 91 94 96 323
Psychotrophic drugs and cognitive function      227—259
Psychotrophic drugs, actions      2
Psychotrophic drugs, development steps of      100
Psychotrophic drugs, effects      1
Psychotrophic drugs, pharmacokinetic studies on      159
Psychotrophic drugs, substances      2
PTSD      see post-traumatic stress disorder
Pulse rate, acceleration of      7 8
Purgativnm      28
Pyridostigmine      89
Pyritinol      88
QALYs      see quality-adjusted life years
QLS      see Quality of life in Schizophrenia instrument
Quality of life      301—302 304 316
Quality of life and pharmacoeconomic analysis      305—307
Quality of Life in Schizophrenia instrument (QLS)      306—307
Quality of life, measurement of      305—306
Quality of life, measurement of, instruments for      306
Quality-adjusted life years (QALYs)      307 309—314 316—317
Quality-adjusted life years (QALYs), analysis of costs per      311
Quazepam      19
Quetiapine      7 5 12 127 177 230—231
Quinine      35
Radioisotopes      208—211
Radioisotopes, types of      208—209
Ranunculaceae      28
Rapid eye movement (REM) sleep      73 82—83 85 87—89 90—91 94 96
Rash      17
Raskin Depression Rating Scale      198
Rating scales      196—197
Rating scales, diagnosis-specific instruments      197—204
Rating scales, diagnosis-specific instruments, anxiety scales      199—200
Rating scales, diagnosis-specific instruments, dementia scales      203
Rating scales, diagnosis-specific instruments, depression scales      197—199
Rating scales, diagnosis-specific instruments, mania scales      202—203
Rating scales, diagnosis-specific instruments, obsessive-compulsive disorder scales      201
Rating scales, diagnosis-specific instruments, psychosis scales      201—202
Rating scales, diagnosis-specific instruments, PTSD scales      201
Rating scales, diagnosis-specific instruments, substance use scales      204
Rating scales, general diagnostic instruments      197 204—205
Rating scales, psychiatric diagnostic scales      197
Rats, anxiety (high/low) lines      138
Rats, effects of reserpine/imipramine on      118
Rats, effects of sigma ligands on      123
Rats, Flinders sensitive/resistant      138
Rats, knockout strains      139
Rats, laboratory tests, and      132 134 136—137
Rats, Roman high/low avoidance      138
Rats, tigmotaxis in      130
Rats, Wistar Kyoto      137
Rauwolfia      27 112
Rauwolfia, remedy for snake bites      29
Rauwolfia, sedative properties of      29
Rauwolfia, serpentina      29
Reality, sense of      21
Reasoning and concept formation      69—70
Reboxetine      11 14 122 238
Receptor occupancy theory      221—224
Receptors      104 106—107
Receptors, blockade of      116 126—127
Receptors, GABA-A      106—107
Receptors, histaminic      90
Receptors, interaction with ligands      109
Receptors, ionotropic      106
Receptors, metabotropic      106
Receptors, muscarinic      52 90
Receptors, naming convention for      106
Receptors, noradrenergic      90
Relatives of patients      274
Release      105
rem      see rapid eye movement sleep
Remeron $\textregistered$       11
Reminyl $\textregistered$       26 53 255
Renal impairment      194
Research and development (R&D)      145—148
Research and development (R&D), methodological issues      147
Research and development (R&D), strategy for      146—147
Research and development (R&D), target product profile      147
Research Diagnostic Criteria      284 286
Reserpine      29 112—113 118
Reserpine and catecholamines      119
Reserpine and depression      120
Reserpine and serotonin      119
Reserpine, syndrome      41
Restlessness      14 21
Restoril $\textregistered$       19
Reuptake, inhibition of      126
Reversible inhibitor of monoamine oxidase activity (RIMA)      11 14
Rhone-Poulenc      37—39 41 49
Rigor      8
RIMA      see reversible inhibitor of monoamine oxidase activity
Risperdal $\textregistered$       5
Risperidone      5 6 161 279
Risperidone, discovery/introduction of      51—52 55 117
Risperidone, receptor blockades by      127
Risperidone, studies/trials of      177 230—233 266—267

1 2 3 4 5 6 7 8

О проекте